These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 12154041

  • 1. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma.
    Tanwar MK, Gilbert MR, Holland EC.
    Cancer Res; 2002 Aug 01; 62(15):4364-8. PubMed ID: 12154041
    [Abstract] [Full Text] [Related]

  • 2. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
    Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC.
    Clin Cancer Res; 2006 Oct 01; 12(19):5698-704. PubMed ID: 17020973
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis.
    Ljubimova JY, Lakhter AJ, Loksh A, Yong WH, Riedinger MS, Miner JH, Sorokin LM, Ljubimov AV, Black KL.
    Cancer Res; 2001 Jul 15; 61(14):5601-10. PubMed ID: 11454714
    [Abstract] [Full Text] [Related]

  • 4. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis.
    Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, Sridevi S, Vrinda M, Arivazhagan A, Balasubramaniam A, Hegde AS, Chandramouli BA, Santosh V, Rao MR, Kondaiah P, Somasundaram K.
    Cancer Epidemiol Biomarkers Prev; 2010 Jun 15; 19(6):1409-22. PubMed ID: 20530493
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.
    Gállego Pérez-Larraya J, Paris S, Idbaih A, Dehais C, Laigle-Donadey F, Navarro S, Capelle L, Mokhtari K, Marie Y, Sanson M, Hoang-Xuan K, Delattre JY, Mallet A.
    Cancer; 2014 Dec 15; 120(24):3972-80. PubMed ID: 25139333
    [Abstract] [Full Text] [Related]

  • 6. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
    Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, Sabbatini P, Hensley ML, Konner J, Tew W, Spriggs D, Fleisher M, Thaler H, Dupont J.
    Gynecol Oncol; 2007 Feb 15; 104(2):435-42. PubMed ID: 17023034
    [Abstract] [Full Text] [Related]

  • 7. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells.
    Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PE.
    Cancer Sci; 2005 Mar 15; 96(3):183-90. PubMed ID: 15771622
    [Abstract] [Full Text] [Related]

  • 8. Protein and mRNA levels of YKL-40 in high-grade glioma.
    Kazakova MH, Staneva DN, Koev IG, Staikov DG, Mateva N, Timonov PT, Miloshev GA, Sarafian VS.
    Folia Biol (Praha); 2014 Mar 15; 60(6):261-7. PubMed ID: 25629266
    [Abstract] [Full Text] [Related]

  • 9. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma.
    Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, Colman H, Yang H, Ledoux A, Blair H, Passe S, Jenkins RB, Aldape KD.
    Clin Cancer Res; 2005 May 01; 11(9):3326-34. PubMed ID: 15867231
    [Abstract] [Full Text] [Related]

  • 10. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas.
    Horbinski C, Wang G, Wiley CA.
    Int J Clin Exp Pathol; 2010 Jan 01; 3(3):226-37. PubMed ID: 20224722
    [Abstract] [Full Text] [Related]

  • 11. Resveratrol represses YKL-40 expression in human glioma U87 cells.
    Zhang W, Murao K, Zhang X, Matsumoto K, Diah S, Okada M, Miyake K, Kawai N, Fei Z, Tamiya T.
    BMC Cancer; 2010 Oct 28; 10():593. PubMed ID: 21029458
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma.
    Saidi A, Javerzat S, Bellahcène A, De Vos J, Bello L, Castronovo V, Deprez M, Loiseau H, Bikfalvi A, Hagedorn M.
    Int J Cancer; 2008 May 15; 122(10):2187-98. PubMed ID: 18092325
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Serum YKL-40, a new prognostic biomarker in cancer patients?
    Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA.
    Cancer Epidemiol Biomarkers Prev; 2006 Feb 15; 15(2):194-202. PubMed ID: 16492905
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
    Johansen JS, Christensen IJ, Riisbro R, Greenall M, Han C, Price PA, Smith K, Brünner N, Harris AL.
    Breast Cancer Res Treat; 2003 Jul 15; 80(1):15-21. PubMed ID: 12889595
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
    Jensen BV, Johansen JS, Price PA.
    Clin Cancer Res; 2003 Oct 01; 9(12):4423-34. PubMed ID: 14555515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.